BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilar immune biologics will erode $10.8 billion in immune biologics brand sales in 2019 alone across the U.S., EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan. According to Biosimilars Advisory Service: Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease, competition between branded and biosimilar TNF-alpha inhibitors and pressure to reduce costs through biosimilars use will contribute to a substantial erosion of brand sales.
Biosimilars' anticipated lower costs compared with branded biologics will be a major driver of their use among both U.S. and European gastroenterologists and rheumatologists. The majority of surveyed U.S. physicians in these specialties say that a policy that reduces or eliminates out-of-pocket costs for patients would significantly or moderately increase their prescribing of biosimilars. In France and Germany, where the cost burden on patients with serious disease is minimal, surveyed gastroenterologists and rheumatologists indicate biosimilars' potential to lower costs to their institutions and clinics will be a key driver of biosimilar use.
"While sales and costs associated with immune biologics, and TNF-alpha inhibitors in particular, make these agents an attractive target for manufacturers and payers, the extent to which biosimilars are able to reduce costs may be limited because of two main factors," said Decision Resources Analyst MaryEllen Klusacek, Ph.D. "First, high development and manufacturing costs for TNF-alpha inhibitors will likely prevent biosimilars in this class from being as steeply discounted as generic small molecule therapies. Second, our primary research suggests that gastroenterologists and rheumatologists will exhibit fairly conservative attitudes toward biosimilar uptake."
The Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German gastroenterologists and rheumatologists to highlight the key expectations that will drive or constrain biosimilar adoption.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources, Inc.
SOURCE Decision Resources